CRMD

CorMedix Inc. Healthcare - Biotechnology Investor Relations →

YES
35.4% BELOW
↓ Approaching Was -26.2% last week
-15% -10% -5% 0% 5% 10% 15%+
Signal Threshold $7.21
14-Week RSI 29 📉
Rel. Volume (14w) This week's trading vs. the 14-week average 2.0x — Surging
Buyers vs. Sellers (14w) Are up-weeks or down-weeks getting more volume? 0.76

CorMedix Inc. (CRMD) closed at $4.66 as of 2026-11-13, trading 35.4% below its 200-week moving average of $7.21. This places CRMD in the extreme value zone. The stock is currently moving closer to the line, down from -26.2% last week. With a 14-week RSI of 29, CRMD is in oversold territory.

A big spike in selling this week — 2.0x the usual volume, and the price dropped. Sometimes this kind of heavy selling marks the end of a decline. The idea is that the last reluctant holders have finally sold, leaving fewer sellers left to push the price lower.

Over the past 813 weeks of data, CRMD has crossed below its 200-week moving average 19 times. On average, these episodes lasted 25 weeks. The average one-year return after crossing below was -3.9%, suggesting these dips have not historically been reliable buying opportunities for this stock.

With a market cap of $371 million, CRMD is a small-cap stock. The company generates a free cash flow yield of 77.9%, which is notably high. Return on equity stands at 15.3%, a solid level. The stock trades at 0.8x book value.

Share count has increased 85.1% over three years, indicating dilution. CRMD passes our Buffett quality screen: high return on equity, low debt, and positive free cash flow. This stock also meets the Yartseva multibagger criteria as a small-cap with strong free cash flow yield and reasonable book value.

Over the past 15.7 years, a hypothetical investment of $100 in CRMD would have grown to $50, compared to $725 for the S&P 500. CRMD has returned -4.3% annualized vs 13.5% for the index, underperforming the broader market over this period.

Free cash flow has been declining. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.

Business Health

Annual financials — how the underlying business has performed over the past several years.

Cash Flow Free cash flow & net income ($M)

Revenue Annual revenue ($M) — business growth proxy

Total Debt Balance sheet debt ($M)

ROIC Return on invested capital (%)

FCF Yield Free cash flow / market cap (%) — Yartseva signal

Gross Margin Pricing power & competitive moat (%)

Shares Outstanding Buybacks vs dilution (millions)

Growth of $100: CRMD vs S&P 500

Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.

What Happens After CRMD Crosses Below the Line?

Across 18 historical episodes, buying CRMD when it crossed below its 200-week moving average produced an average return of -7.2% after 12 months (median -25.0%), compared to +13.1% for the S&P 500 over the same periods. 29% of those episodes were profitable after one year. After 24 months, the average return was -25.9% vs +33.0% for the index.

Each line shows $100 invested at the moment CRMD crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.

Bean Score Experimental

The Bean Score measures how far a stock's free cash flow yield has deviated from its own quarterly baseline, normalized by the stock's historical behavior. Between earnings dates, FCF is constant — so the score is purely a function of stock price. The levels below show at what prices CRMD would reach each dislocation threshold.

Current Bean Score +3.12σ
Current FCF Yield 83.06%
Baseline Yield 53.83%
Historical σ 7.56pp

Dislocation Price Levels

Prices where CRMD's Bean Score would hit each σ threshold. Valid until next earnings report (date TBD — last report: 2026-09-30).

LevelσPriceSignal
Deep Value+2σ$5.19Unusually cheap — analysis point
Value+1σ$5.77Cheap vs. own history
Fair Value+0σ$6.51Historical mean behavior
Expensive-1σ$7.45Expensive vs. own history
Deep Expensive-2σ$8.72Unusually expensive — analysis point

Quarterly FCF & Yield Trailing twelve-month free cash flow and yield at each quarter end

Recent Earnings

DateEPS Est.EPS ActualSurprise
2026-11-12$-0.11$-0.19-65.2%
2026-08-13$0.24$0.29+21.9%
2026-05-14$0.33$0.35+5.9%
2026-03-05$0.81$0.16-80.2%
Data depth: 2 quarterly baselines, 19 price observations — Limited history (4+ quarters preferred for reliability)

Signal Accuracy Collecting Data

The Bean Score system is accumulating weekly data to validate signal accuracy. After 13+ weeks of history, this section will display win rates and average returns for each σ threshold crossing — answering the question: "When this score says cheap or expensive, does the price subsequently move in the expected direction?"

21 / 13 weeks minimum

the write-ups I read Simply Wall St · Visual company reports and write-ups. Free tier covers five reports a month. referral

Theoretical framework — not backtested or forward-tested. The Bean Score uses trailing twelve-month free cash flow yield as a dislocation identifier. It measures whether the market has pushed a stock's yield unusually far from its own baseline behavior. These levels are analysis points: prices at which the yield deviation becomes unusual enough to justify the work. FCF values update quarterly with earnings; between reports, all movement is price-driven.

Dislocation Scores Experimental

Each score measures deviation from CRMD's own historical baseline — the same idea as the Bean Score, applied to different fundamentals. Positive means cheaper or more dislocated than this stock's norm. Scores marked σ are normalized by the stock's own variability; pp values are simple deltas from its recent baseline.

Yield Dislocation N/A Dividend yield vs own 10-yr norm
Drawdown Score +0.50σ Distance from line vs own history
Sector-Relative +0.37σ Vs sector median this week
Buyback Acceleration +0.3pp YoY share change vs own 3-yr pace (− = accelerating)
Insider Intensity N/A TTM buys / market cap, percentile of buyers
FCF Yield vs History +76.8pp Vs own recent annual mean
Earnings Quality Insufficient data Accrual gap trend

Theoretical framework — not backtested. These scores describe how unusual today's readings are for this specific company. Each one is an analysis point, a reason to open the filings. Annual-statement scores (buyback, accruals, FCF vs history) rest on only ~4 yearly data points and are deltas, not sigmas.

Historical Touches

CRMD has crossed below its 200-week MA 19 times with an average 1-year return of +-3.9% after recovery.

Crossed BelowRecoveredWeeksMax Depth1-Year ReturnReturn Since Touch
Apr 2011Apr 201110.8%-79.5%-47.0%
May 2011Dec 201313785.1%-82.9%-45.2%
Dec 2015Dec 201512.1%-5.4%-49.3%
Jan 2016Feb 2016835.7%+6.1%-43.5%
Jun 2016Sep 20161432.9%-80.0%-56.7%
Oct 2016Jan 201912091.8%-72.2%-59.5%
Feb 2019Feb 201911.1%-25.4%-44.9%
May 2019Jun 2019310.6%-36.3%-32.3%
Sep 2019Dec 20191122.0%-22.2%-30.2%
Jan 2020Feb 202010.2%+37.8%-26.6%
Feb 2020Jun 20201454.2%+188.5%-10.4%
Jul 2020Sep 2020824.0%+30.6%+4.7%
Oct 2020Nov 202011.5%-3.8%-7.7%
Jul 2021Aug 202110.5%-7.9%-19.8%
Aug 2021Aug 202110.2%-33.4%-20.6%
Sep 2021Apr 202413556.2%-19.7%+0.6%
May 2024Aug 20241425.7%+139.8%-9.0%
Mar 2026Mar 202634.9%N/A-27.9%
Oct 2026Ongoing3+35.4%Ongoing-18.2%
Average25—+-3.9%—

Frequently Asked Questions

Is CRMD below its 200-week moving average?

Yes. As of 2026-11-13, CorMedix Inc. (CRMD) is trading 35.4% below its 200-week moving average of $7.21. The current price is $4.66.

What is CRMD's 200-week moving average price?

CorMedix Inc.'s 200-week moving average is $7.21 as of 2026-11-13. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.

What happens when CRMD drops below its 200-week moving average?

CRMD has crossed below its 200-week moving average 19 times in our data. The average one-year return after these crossings was -3.9%, meaning the dips were not reliable buying signals for this particular stock. These episodes lasted 25 weeks on average.

Is CRMD a good value right now?

Here's what our data says about CRMD as of 2026-11-13: The stock is below its 200-week moving average, which is the starting point for our analysis. The 14-week RSI is 29 (oversold). Free cash flow yield is 77.9%. Return on equity is 15.3%. Price-to-book is 0.8x. This is not a buy or sell recommendation — always do your own research.

How does CRMD compare to the S&P 500?

Over the past 15.7 years, $100 invested in CRMD would have grown to $50, compared to $725 for the S&P 500. That's -4.3% annualized vs 13.5% for the index. CRMD has underperformed the broader market over this period.

Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.

Data as of week of 2026-11-13